NASDAQ:ARDM - Aradigm Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.61 +0.07 (+12.96 %) (As of 12/11/2018 02:40 AM ET)Previous Close$0.54Today's Range$0.54 - $0.6252-Week Range$0.50 - $7.35Volume67,200 shsAverage Volume137,134 shsMarket Capitalization$8.26 millionP/E Ratio-0.81Dividend YieldN/ABeta0.72 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Aradigm Corporation, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. Its lead development candidates are proprietary formulations of the potent antibiotic ciprofloxacin, including Linhaliq and Lipoquin that are delivered by inhalation for the management of infections associated with severe respiratory diseases, including non-cystic fibrosis bronchiectasis, cystic fibrosis, and non-tuberculosis mycobacterium. The company is also developing inhaled ciprofloxacin formulations for treatment of patients with cystic fibrosis, and has tested for the prevention and treatment of inhaled bioterrorism infections, such as Coxiella burnetii or Q fever, inhalation anthrax, tularemia, melioidosis and pneumonic plague. Aradigm Corporation has collaboration agreements with Grifols, S.A. The company was founded in 1991 and is headquartered in Hayward, California. Receive ARDM News and Ratings via Email Sign-up to receive the latest news and ratings for ARDM and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Electromedical equipment Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ARDM Previous Symbol CUSIPN/A Webwww.aradigm.com Phone510-265-9000 Debt Debt-to-Equity RatioN/A Current Ratio1.23 Quick Ratio1.23 Price-To-Earnings Trailing P/E Ratio-0.81 Forward P/E Ratio-0.57 P/E GrowthN/A Sales & Book Value Annual Sales$14.47 million Price / Sales0.64 Cash FlowN/A Price / Cash FlowN/A Book Value($0.83) per share Price / Book-0.73 Profitability EPS (Most Recent Fiscal Year)($0.72) Net Income$-10,700,000.00 Net Margins-374.80% Return on EquityN/A Return on Assets-374.15% Miscellaneous Employees23 Outstanding Shares15,220,000Market Cap$8.26 million OptionableOptionable Aradigm (NASDAQ:ARDM) Frequently Asked Questions What is Aradigm's stock symbol? Aradigm trades on the NASDAQ under the ticker symbol "ARDM." How were Aradigm's earnings last quarter? Aradigm Co. (NASDAQ:ARDM) issued its earnings results on Thursday, November, 15th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.21) by $0.03. The business had revenue of $0.28 million for the quarter. View Aradigm's Earnings History. When is Aradigm's next earnings date? Aradigm is scheduled to release their next quarterly earnings announcement on Friday, March 22nd 2019. View Earnings Estimates for Aradigm. What is the consensus analysts' recommendation for Aradigm? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aradigm in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Aradigm. Has Aradigm been receiving favorable news coverage? Headlines about ARDM stock have trended somewhat positive recently, according to InfoTrie. The research group identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Aradigm earned a daily sentiment score of 1.0 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days. Who are some of Aradigm's key competitors? Some companies that are related to Aradigm include Precision Optics (PEYE), Digirad (DRAD), Nexeon Medsystems (NXNN), ENDRA Life Sciences (NDRA), Non-Invasive Monitoring Systems (NIMU), Vaso (VASO), CHF Solutions (CHFS), Escalon Medical (ESMC), SpectraScience (SCIE), Trimedyne (TMED), Magna-Lab (MAGAA), Reshape Lifesciences (RSLS), Guided Therapeutics (GTHP), 21st North (ULGX) and Newcardio (NWCI). Who are Aradigm's key executives? Aradigm's management team includes the folowing people: Dr. John M. Siebert, Exec. Chairman, Interim Principal Exec. Officer & Acting Principal Financial Officer (Age 78)Dr. Juergen Froehlich M.D., MBA, FCPh, Chief Medical Officer (Age 61)Lisa Thomas, Corp. Controller How do I buy shares of Aradigm? Shares of ARDM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Aradigm's stock price today? One share of ARDM stock can currently be purchased for approximately $0.61. How big of a company is Aradigm? Aradigm has a market capitalization of $8.26 million and generates $14.47 million in revenue each year. The company earns $-10,700,000.00 in net income (profit) each year or ($0.72) on an earnings per share basis. Aradigm employs 23 workers across the globe. What is Aradigm's official website? The official website for Aradigm is http://www.aradigm.com. How can I contact Aradigm? Aradigm's mailing address is 3929 POINT EDEN WAY, HAYWARD CA, 94545. The company can be reached via phone at 510-265-9000 or via email at [email protected] MarketBeat Community Rating for Aradigm (NASDAQ ARDM)Community Ranking: 2.0 out of 5 ( )Outperform Votes: 146 (Vote Outperform)Underperform Votes: 213 (Vote Underperform)Total Votes: 359MarketBeat's community ratings are surveys of what our community members think about Aradigm and other stocks. Vote "Outperform" if you believe ARDM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARDM will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/11/2018 by MarketBeat.com StaffFeatured Article: What is the Coverage Ratio?